2023 CBIIC in Suzhou Industrial Park on September 25-27, 2023.


Dr. Li Chen, Executive Director, Chief Executive Officer,founded and leads Hua Medicine to discover and develop clinically differentiated medicine in China for Global. Under his leadership, Hua Medicine has successfully brought an disease modifying first-in-class glucokinase activator (GKA)HuaTangNing(华堂宁®) (dorzagliatin tablets, HMS5552) into China market. Dorzagliatin is approved by the National Medical Products Administration (NMPA) of China for Type 2 Diabetes with its unique mechanism of action in restoring the impaired glucose homeostasis. During this period, Hua Medicine raised 200M USD and established commercialization capabilities of HuaTangNing with strategic partnership in manufacturing, marketing and sales, as well as national distributors.

Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 80 granted patents, 213 patent applications and an author with about 70 publications including Nature Medicine, Lancet Diabetes and Endocrinology, Diabetes, Diabetes obesity and metabolism, PNAS, JACS and JOC.